PTCH1 and medulloblastoma: Importantly, in GS, genetic validation allows targeted management by linking genotype to phenotype: SUFU mutation carriers benefit from early and intensive neuroimaging surveillance due to high medulloblastoma risk, whereas PTCH1 mutation carriers require long-term dermatologic monitoring for basal cell carcinoma [6].